PICI Network Investigators to Showcase Immunotherapy Advances at ASCO 2024

One of the largest events for the oncology community, the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, is set to take place Friday, May 31- Tuesday, June 4, in Chicago. Researchers from around the globe will present latest innovations in cancer research and treatments, and PICI Network Investigators and Collaborators will be at the epicenter of many significant developments in immunotherapy. 

PICI Investigators are advancing immunotherapy science through numerous cancer studies across various cancer types and phases, presenting their work at ASCO 2024 while driving scientific discourse as session chairs and fostering collaborations that will inspire future innovation. 

In total, PICI network investigators and collaborators are involved in more than 35 presentations, including:

• 2 keynotes and special sessions 
• 5 oral and rapid oral presentations as contributing authors
• More than 25 poster presentations 
• 6 e-publication papers 

Keynote Presentations and Special Sessions:

• PICI Investigator Philip Greenberg, MD (Fred Hutch), who served as 2023-24 AACR President, will present welcome and introductory remarks and serve as session chair as part of a special session, “ASCO/AACR Joint Session: Drugging the “Undruggable” Target: Successes, Challenges, and the Road Ahead”
• PICI Center Director Jedd Wolchok, MD, PhD  (Weill Cornell Medicine) will chair an education session focused on advances in melanoma, entitled “Implementing the Future Where There is Cure for All” 

Presentation Highlights from the Network: 

• PICI Center Co-Director Elizabeth A. Mittendorf, MD, PhD (Dana-Farber Cancer Institute): SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer (LBA1004)
• PICI Center Co-Director F. Stephen Hodi, MD (Dana-Farber): Interleukin-6 receptor blockade with tocilizumab to reduce immune-related toxicity with ipilimumab and nivolumab in metastatic melanoma (9538)
• PICI Investigator Eliezer Van Allen, MD (Dana-Farber): Whole exome correlates in metastatic hormone sensitive prostate cancer (mHSPC): Results from E3805 CHAARTED (5088)
• PICI Center Director Carl June, MD (University of Pennsylvania), PICI Investigator Joseph Fraietta, PhD (UPenn): Safety and efficacy of armored huCART19-IL18 in patients with relapsed/refractory lymphomas that progressed after anti-CD19 CAR T cells (7004)
• PICI Center Co-director Saar Gill, MBBS, PhD, FRACP (Penn): A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation (TPS2678)
• PICI Investigator Robert Vonderheide, MD, DPhil (Penn) and co-authors including PICI Chief Medical Officer Ute Dugan, MD, PhD, and PICI Senior Director, Network Clinical Research, Chris Cabanski, PhD: Clinical and translational results from REVOLUTION cohorts A (nivolumab + ipilimumab + chemotherapy) and B (hydroxychloroquine + ipilimumab + chemotherapy) in patients with previously untreated metastatic pancreatic adenocarcinoma. (4137)
• PICI Center Director Antoni Ribas MD, PhD (University of California, Los Angeles):  Association between circulating tumor DNA (ctDNA) and recurrence-free survival (RFS) in patients (pts) with resected stage III melanoma: An exploratory analysis of SWOG S1404. (9564)
• PICI Center Co-Director Lawrence Fong, MD (University of California, San Francisco): A phase 1/2 study of REGN7075 in combination with cemiplimab (cemi) in patients (pts) with advanced solid tumors: Efficacy and safety results (2503)
• PICI Investigator Adil Daud, MD (UCSF):  Phase II multi-center study of adjuvant nivolumab in combination with ipilimumab in patients with high-risk uveal melanoma (HCRN MEL17-309) (9509)
• PICI Center Director James P. Allison, PhD (MD Anderson) and PICI Center Co-Director Padmanee Sharma, MD, PhD (MD Anderson): Phase II trial of weekly or bi-weekly tocilizumab with ipilimumab and nivolumab in advanced melanoma: Clinical outcomes and biomarker analysis (9553)
• PICI Collaborator Elizabeth M. Jaffee, MD (Johns Hopkins): Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01. (LBA4004)
• PICI Chief Scientific Officer John Connolly, PhD and PICI Alliances and Collaboration Director Sam Liang, PhD: Use of a tissue-free epigenomic circulating tumor DNA (ctDNA) assay for quantification of tumor fraction (TF) and association with outcomes from RADIOHEAD real-world advanced pan-cancer cohort. (2570)

We look forward to another thought-provoking ASCO annual meeting, with the latest in breakthrough research and collaborative opportunities across our broader scientific community. 

Stay tuned for updates from ASCO 2024, and be sure to follow us on social media for highlights.